The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model
Open accessAbstract
The AKT/mammalian target of rapamycin (AKT/mTOR) and ERK MAPK signaling pathways have been shown to cooperate in prostate cancer progression and the transition to androgen-independent disease. We have now tested the effects of combinatorial inhibition of these pathways on prostate tumorigenicity by performing preclinical studies using a genetically engineered mouse model of prostate cancer. We report here that combination therapy using rapamycin, an inhibitor of mTOR, and PD0325901, an inhibitor of MAPK kinase 1 (MEK; the kinase directly upstream of ERK), inhibited cell growth in cultured prostate cancer cell lines and tumor growth particularly for androgen-independent prostate tumors in the mouse model. We further showed that such inhibition leads to inhibition of proliferation and upregulated expression of the apoptotic regulator Bcl-2-interacting mediator of cell death (Bim). Furthermore, analyses of human prostate cancer tissue microarrays demonstrated that AKT/mTOR and ERK MAPK signaling pathways are often coordinately deregulated during prostate cancer progression in humans. We therefore propose that combination therapy targeting AKT/mTOR and ERK MAPK signaling pathways may be an effective treatment for patients with advanced prostate cancer, in particular those with hormone-refractory disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Targeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt-Leopold, J. S., & Herrera, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1503 · Cited by 1,108
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Paweletz, C. P., Charboneau, L., Bichsel, V. E., Simone, N. L., Chen, T., Gillespie, J. W., Emmert-Buck, M. R., Roth, M. J., Petricoin III, E. F., & Liotta, L. A. (2001) · Oncogene · doi:10.1038/sj.onc.1204265 · Cited by 956
Molecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 942
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938
Roles for Nkx3.1 in prostate development and cancer
Bhatia-Gaur, R., Donjacour, A. A., Sciavolino, P. J., Kim, M., Desai, N., Young, P., Norton, C. R., Gridley, T., Cardiff, R. D., Cunha, G. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.8.966 · Cited by 665
Self-citationMcMenamin, M. E., Soung, P., Perera, S., Kaplan, I. D., Loda, M. F., & Sellers, W. R. (1999) · PubMed · Cited by 640
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Activation of mitogen-activated protein kinase associated with prostate cancer progression.
Gioeli, D. G., Mandell, J. W., Petroni, G. R., Frierson, H. F., & Weber, M. J. (1999) · PubMed · Cited by 541
Pathological and molecular aspects of prostate cancer
DeMarzo, A. M., Nelson, W. G., Isaacs, W. B., & Epstein, J. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12779-1 · Cited by 472
Shah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30890 · Cited by 418
Targeting the ERK signaling pathway in cancer therapy
Kohno, M., & Pouyssegur, J. (2006) · Annals of Medicine · doi:10.1080/07853890600551037 · Cited by 416
Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis
Kim, M. J., Cardiff, R. D., Desai, N., Banach-Petrosky, W. A., Parsons, R., Shen, M. M., & Abate-Shen, C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.042688999 · Cited by 338
Self-citationKuzmichev, A., Margueron, R., Vaquero, A., Preissner, T. S., Scher, M., Kirmizis, A., Ouyang, X., Brockdorff, N., Abate-Shen, C., Farnham, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409875102 · Cited by 336
Self-citationImmunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.
Malik, S. N., Brattain, M. G., Ghosh, P., Troyer, D. A., Prihoda, T. J., Bedolla, R. G., & Kreisberg, J. I. (2002) · PubMed · Cited by 321
Xu, Y., Chen, S.-Y., Ross, K. N., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4472 · Cited by 301
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy
Tan, T.-T., Degenhardt, K., Nelson, D. A., Beaudoin, B., Nieves-Neira, W., Bouillet, P., Villunger, A., Adams, J. M., & White, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.008 · Cited by 284
The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics
Olive, K. P., & Tuveson, D. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0436 · Cited by 244
mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo
Kwon, C.-H., Zhu, X., Zhang, J., & Baker, S. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2132711100 · Cited by 235
Skeen, J. E., Bhaskar, P. T., Chen, C.-C., Chen, W. S., Peng, X.-D., Nogueira, V., Hahn-Windgassen, A., Kiyokawa, H., & Hay, N. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.022 · Cited by 234
Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases.
Abate-Shen, C. T., Banach-Petrosky, W. A., Sun, X., et al. (2003) · PubMed · Cited by 228
Self-citationMouse Models of Brain Tumors and Their Applications in Preclinical Trials
Fomchenko, E. I., & Holland, E. C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0438 · Cited by 226
Abreu-Martin, M. T., Chari, A., Palladino, A. A., Craft, N. A., & Sawyers, C. L. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.5143 · Cited by 216
Fan, Q.-W., Cheng, C. K., Nicolaides, T. P., Hackett, C. S., Knight, Z. A., Shokat, K. M., & Weiss, W. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2154 · Cited by 192
Will mTOR inhibitors make it as cancer drugs?
Sawyers, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00275-7 · Cited by 190
Advances in Prostate Cancer Chemotherapy: A New Era Begins
Pienta, K. J., & Smith, D. C. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.5.300 · Cited by 185
Expression of mTOR signaling pathway markers in prostate cancer progression
Kremer, C. L., Klein, R. R., Mendelson, J., Browne, W., Samadzedeh, L. K., Vanpatten, K., Highstrom, L., Pestano, G. A., & Nagle, R. B. (2006) · The Prostate · doi:10.1002/pros.20410 · Cited by 182
Ouyang, X., Jessen, W. J., Al‐Ahmadie, H. A., Serio, A. M., Lin, Y., Shih, W. J., Reuter, V. E., Scardino, P. T., Shen, M. M., Aronow, B. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6055 · Cited by 146
Self-citationGao, H., Ouyang, X., Banach-Petrosky, W. A., Gerald, W. L., Shen, M. M., & Abate-Shen, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606836103 · Cited by 141
Self-citationSignal transduction in prostate cancer progression
Gioeli, D. G. (2005) · Clinical Science · doi:10.1042/cs20040329 · Cited by 127
Brown, A. P., Carlson, T., Loi, C., & Graziano, M. J. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0323-5 · Cited by 127
A critical role for p27 kip1 gene dosage in a mouse model of prostate carcinogenesis
Gao, H., Ouyang, X., Banach-Petrosky, W. A., Borowsky, A. D., Lin, Y., Kim, M., Lee, H., Shih, W. J., Cardiff, R. D., Shen, M. M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407693101 · Cited by 123
Self-citationUzgare, A. R., & Isaacs, J. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0968 · Cited by 121
BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis: Figure 1.Preprint
Gélinas, C., & White, E. (2005) · Genes & Development · doi:10.1101/gad.1326205 · Cited by 120
Mechanisms of apoptosis regulation by viral oncogenes in infection and tumorigenesis
White, E. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401941 · Cited by 88
The current role of chemotherapy in metastatic hormone-refractory prostate cancer
Petrylak, D. P. (2005) · Urology · doi:10.1016/j.urology.2005.03.053 · Cited by 80
Mouse Modeling in Oncologic Preclinical and Translational Research
Carver, B. S., & Pandolfi, P. P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0482 · Cited by 68
A New Generation of Mouse Models of Cancer for Translational Research
Abate-Shen, C. T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0500 · Cited by 40
Self-citationChemotherapy for androgen-independent prostate cancer
Petrylak, D. P. (2005) · World Journal of Urology · doi:10.1007/s00345-004-0482-0 · Cited by 24
Cited by
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
Metadata
- Authors
- Kinkade, C. W., Castillo-Martin, M., Puzio-Kuter, A., Yan, J., Foster, T. H., Gao, H., Sun, Y., Ouyang, X., Gerald, W. L., Cordon-Cardo, C., & Abate-Shen, C.
- Venue
- Journal of Clinical Investigation
- Published
- 2008-08-01
- Volume
- 118
- Issue
- 9
- Pages
- 3051-64
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2121640179
- Cited by
- 391
- References
- 47
- FWCI
- 38.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.